Skip to search formSkip to main contentSkip to account menu

0.2 ML ocriplasmin 2.5 MG/ML Injection [Jetrea]

Known as: JETREA 0.5 MG in 0.2 ML Injection, Jetrea 0.5 MG per 0.2 ML Injection, OCRIPLASMIN 2.5 mg in 1 mL INTRAVITREAL INJECTION, SOLUTION [JETREA] 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (1)

0.2 ML ocriplasmin 2.5 MG/ML Injection
InjectionJetreaMannitolSodium Hydroxide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Vitreomacular traction syndrome: New non-surgical treatments
introduction: Vitreomacular traction syndrome is described as a maculopathy in which incomplete vitreous detachment associated… 
2018
2018
Ocriplasmin in the Treatment of Vitreomacular Traction in a Patient with Central Retinal Vein Occlusion: A Case Report
Aim: To investigate the efficacy of intravitreal injection of ocriplasmin (JETREA®) in the treatment of vitreomacular traction… 
2018
2018
[Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
PURPOSE In vitreomacular traction (VMT), there is abnormal adhesion between the vitreous cortex and the retina, especially in the… 
Review
2018
Review
2018
Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA.
BACKGROUND Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin… 
2016
2016
Unklare Retinopathie nach intravitrealer Eingabe von Ocriplasmin
ZusammenfassungFallbeschreibungEs wird über den Fall einer 50-jährigen Patientin berichtet, die bei fokaler vitreomakulärer… 
2016
2016
Tracción vitreomacular: Nuevos tratamientos no-quirúrgicos
2015
2015
Jetrea® (Ocriplasmin) as a treatment option for symptomatic vitreomacular traction with or without macular hole (≤400 µm) in comparison to transconjunctival vitrectomy
2014
2014
Ocriplasmin: a guide to its use in symptomatic vitreomacular adhesion
Ocriplasmin (Jetrea®) is a stable, recombinant, truncated form of human serine protease plasmin that has proteolytic activity… 
2013
2013
EMA har godkänt Jetrea® (ocriplasmin), det första och enda ögonläkemedlet för behandling av det synhotande tillståndet VMT (glaskroppsdragning i gula fläcken) och makulahål
EMA har godkant Jetrea® (ocriplasmin), det forsta och enda ogonlakemedlet for behandling av det synhotande tillstandet VMT… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)